---
title: "Antengene Schedules Board Meeting to Approve 2025 Annual Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278457077.md"
description: "Antengene Corporation Limited (HK:6996) will hold a board meeting on March 20, 2026, to approve its annual results for the financial year ending December 31, 2025. This meeting is crucial for investors as it will address the publication of the results, reflecting the company's financial performance and governance. The board includes key executives and independent directors, ensuring compliance with Hong Kong listing requirements. The latest analyst rating for Antengene's stock is a Sell, with a price target of HK$3.00, and the company has a market cap of HK$2.48B."
datetime: "2026-03-09T22:37:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278457077.md)
  - [en](https://longbridge.com/en/news/278457077.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278457077.md)
---

# Antengene Schedules Board Meeting to Approve 2025 Annual Results

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

An update from Antengene Corporation Limited ( (HK:6996) ) is now available.

Antengene Corporation Limited has announced that its board of directors will convene on March 20, 2026, to review and approve the annual results of the company and its subsidiaries for the financial year ended December 31, 2025. The meeting will also address the publication of these results, a key disclosure event for investors and other stakeholders monitoring the company’s financial performance and governance.

The board currently comprises Chairman and executive director Dr. Jay Mei, executive director Mr. Donald A. Lung, and independent non-executive directors Ms. Jing Qian, Mr. Sheng Tang, and Dr. Rafael Fonseca. The composition underscores the company’s adherence to Hong Kong listing governance requirements, and the upcoming results announcement is likely to provide further insight into Antengene’s operational progress and strategic positioning over the past year.

The most recent analyst rating on (HK:6996) stock is a Sell with a HK$3.00 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.

**More about Antengene Corporation Limited**

Antengene Corporation Limited is a biopharmaceutical company listed on the Hong Kong Stock Exchange under stock code 6996. The company focuses on the discovery, development, and commercialization of innovative therapies, operating through a group structure that includes multiple subsidiaries.

**YTD Price Performance:** 3.17%

**Average Trading Volume:** 2,772,955

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$2.48B

Find detailed analytics on 6996 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [06996.HK](https://longbridge.com/en/quote/06996.HK.md)

## Related News & Research

- [Antengene Corp says Xpovio approved in Hong Kong for two additional indications](https://longbridge.com/en/news/268383600.md)
- [Prediction: Buying This Biotech Stock Today Could Set You Up for Life](https://longbridge.com/en/news/282523846.md)
- [Henlius Wins China Nod to Expand Indications for Rituximab Biosimilar HANLIKANG](https://longbridge.com/en/news/282177167.md)
- [S.Korea pension fund to continue discussing with FX authorities about its macroeconomic impact, FX hedging policy - Welfare Ministry](https://longbridge.com/en/news/282656433.md)
- [Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline](https://longbridge.com/en/news/282670202.md)